Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial

World Journal of Gastroenterology

Volumn 18, Issue 18, 2012, Pages 2203-2211

  Oliveira, Lucivalda P M ^a   De Jesus, Rosangela P ^a   Boulhosa, Ramona S S B ^a   Mendes, Carlos Mauricio C ^a   Gnoatto, Maria Cecilia ^a   Lemaire, Denise C ^a   Toralles, Maria Betania P ^a   Cavalcante, Lourianne N ^a   Lyra, Andre C ^a,b   Lyra, Luiz G C ^a,b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b HOSPITAL SÃO RAFAEL   (Brazil)

Author keywords

Chronic hepatitis C; Hepatic steatosis; Hepatitis C virus; Insulin resistance; Soy supplementation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CASEIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; SOYBEAN PROTEIN; BIOLOGICAL MARKER;

ABDOMINAL FAT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS C; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEMOGRAPHY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE SEVERITY; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL SUPPORT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; SOCIAL STATUS; WAIST CIRCUMFERENCE; BLOOD; BRAZIL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEPATITIS C; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK; RISK ASSESSMENT; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; BRAZIL; DIETARY SUPPLEMENTS; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SINGLE-BLIND METHOD; SOYBEAN PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866245688     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i18.2203     Document Type: Article

References (40)

1. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008; 22: 991-1008
2. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-1008
3. Delgado-Borrego A, Liu YS, Jordan SH, Agrawal S, Zhang H, Christofi M, Casson D, Cosimi AB, Chung RT. Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl 2008; 14: 193-201
4. Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut 2005; 54: 903-906
5. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40 Suppl 1: S34-S38
6. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 2007; 86: 285-300
7. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 Suppl 1: S17-S29
8. Romero-Gmez M. Hepatitis C and insulin resistance: steatosis, fibrosis and non-response. Revista Espanola de Enfermedades Digestivas 2006; 98: 605-615
9. Lecube A, Hernández C, Genescà J, Simó R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. Diabetes Care 2006; 29: 1096-1101
10. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508
11. Del Campo JA, Romero-Gómez M. Steatosis and insulin resistance in hepatitis C: a way out for the virus? World J Gastroenterol 2009; 15: 5014-5019
12. He Q, Graham CS, Durante Mangoni E, Koziel MJ. Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C. Liver Int 2006; 26: 1100-1110
13. Jayagopal V, Albertazzi P, Kilpatrick ES, Howarth EM, Jennings PE, Hepburn DA, Atkin SL. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care 2002; 25: 1709-1714
14. Barnes S. Evolution of the health benefits of soy isoflavones. Proc Soc Exp Biol Med 1998; 217: 386-392
15. Park D, Huang T, Frishman WH. Phytoestrogens as cardioprotective agents. Cardiol Rev 2005; 13: 13-17
16. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986; 292: 13-15
17. Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995; 311: 1401-1405
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
19. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20
20. R Foundation For Statistical Computing R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available from: URL: http://www.r-project. org. Accessed October 2010
21. Parise ER, Oliveira AC. [Insulin resistance in chronic hepatitits C]. Arq Gastroenterol 2007; 44: 178-184
22. Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, Adinolfi LE, Ruggiero G, Carulli N, Loria P. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 2006; 44: 190-196
23. Giannini C, Giannelli F, Monti M, Careccia G, Marrocchi ME, Laffi G, Gentilini P, Zignego AL. Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. J Lab Clin Med 1999; 134: 68-73
24. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35: 531-537
25. Kobayashi Y, Kawaguchi Y, Mizuta T, Kuwashiro T, Oeda S, Oza N, Takahashi H, Iwane S, Eguchi Y, Anzai K, Ozaki I, Fujimoto K. Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C. J Gastroenterol 2011; 46: 529-535
26. Lo Iacono O, Venezia G, Petta S, Mineo C, De Lisi S, Di Marco V, Rodolico V, Amato M, Ferraro D, Giordano C, Almasio PL, Craxí A. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 1181-1191
27. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, Brun JM, Hillon P. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35: 279-283
28. Gudbrandsen OA, Wergedahl H, Berge RK. A casein diet added isoflavone-enriched soy protein favorably affects biomarkers of steatohepatitis in obese Zucker rats. Nutrition 2009; 25: 574-580
29. Peluso MR, Winters TA, Shanahan MF, Banz WJ. A cooperative interaction between soy protein and its isoflavoneenriched fraction lowers hepatic lipids in male obese Zucker rats and reduces blood platelet sensitivity in male Sprague-Dawley rats. J Nutr 2000; 130: 2333-2342
30. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1135-G1139
31. Yu J, Chu ES, Wang R, Wang S, Wu CW, Wong VW, Chan HL, Farrell GC, Sung JJ. Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice. Gastroenterology 2010; 138: 694-704, 704.e1
32. Gudbrandsen OA, Wergedahl H, Mørk S, Liaset B, Espe M, Berge RK. Dietary soya protein concentrate enriched with isoflavones reduced fatty liver, increased hepatic fatty acid oxidation and decreased the hepatic mRNA level of VLDL receptor in obese Zucker rats. Br J Nutr 2006; 96: 249-257
33. Wiseman H, O'Reilly JD, Adlercreutz H, Mallet AI, Bowey EA, Rowland IR, Sanders TA. Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr 2000; 72: 395-400
34. Negro F. Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance. PPAR Res 2009; 2009: 483485
35. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int 2009; 29 Suppl 2: 13-25
36. Younossi ZM, McCullough AJ. Metabolic syndrome, nonalcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009; 29 Suppl 2: 3-12
37. Abdel-Azziz MY, Zalata KR, El-Bendary MM. Insulin resistance and liver fibrosis progression in patients with chronic hepatitis C virus infection. Arab J Gastroenterol 2010; 11: 30-34
38. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 28: 503-522
39. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599
40. Kim CH, Kallman JB, Bai C, Pawloski L, Gewa C, Arsalla A, Sabatella ME, Younossi ZM. Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes Surg 2010; 20: 154-160